According to @StockMKTNewz, Eli Lilly LLY said its oral weight loss pill helped patients maintain the majority of their weight loss after a direct switch from Wegovy and Zepbound injections in a late-stage trial, per CNBC. CNBC reported the update as company-disclosed late-stage data focused on maintenance of prior weight loss following the switch from injectable regimens, with no crypto market impact noted in the cited report.